Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients

Publisher： Karger

E-ISSN： 1421-9913|61|3|177-182

ISSN： 0014-3022

Source： European Neurology, Vol.61, Iss.3, 2009-01, pp. : 177-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study

By  

European Neurology, Vol. 72, Iss. 3-4, 2014-09 ,pp. : 173-180

Karger

Access to resources Recommend Favorite

Is Interferon Effective and Safe for Relapsing-Remitting Multiple Sclerosis?

By  

Neuroepidemiology, Vol. 21, Iss. 6, 2002-11 ,pp. : 310-

Karger

Access to resources Recommend Favorite

CXCL11 (Interferon-Inducible T-Cell Alpha Chemoattractant) and Interleukin-18 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Methylprednisolone

By  

European Neurology, Vol. 58, Iss. 4, 2007-09 ,pp. : 228-232

Karger

Access to resources Recommend Favorite

Azathioprine and Interferon β1a in Relapsing-Remitting Multiple Sclerosis Patients: Increasing Efficacy of Combined Treatment

By  

European Neurology, Vol. 51, Iss. 1, 2004-01 ,pp. : 15-20

Karger

Access to resources Recommend Favorite

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

By  

European Neurology, Vol. 59, Iss. 3-4, 2007-11 ,pp. : 131-135

Karger

Access to resources Recommend Favorite